Tag: Evolocumab

1. Compared to those treated with only standard therapy, patients treated with the addition of evolocumab, a monoclonal antibody that inhibits activity of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9), experienced significantly lower serum LDL levels and lower rates of cardiovascular events at 1 year compared to placebo. 2....
1. : In patients with homozygous familial hypercholesterolemia, evolocumab significantly reduced LDL cholesterol levels. The regimen was well-tolerated with no serious adverse events reported in 33 patients. 2. : In patients with heterozygous familial hypercholesterolemia, evolocumab significantly reduced LDL cholesterol levels. Among the 220 patients receiving evolocumab, there were...
Image: PD  1. When paired with statin therapy, evolocumab greatly reduced patient low-density lipoprotein cholesterol (LDL-C) levels compared to placebo or ezetimibe.  2. Evolocumab paired with statin therapy reduced LDL-C levels in patients independent of statin type or treatment intensity across the three most common statins.  Evidence Rating Level: 1 (Excellent)  ...
Image: PD In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an integral protein in the LDL cholesterol degradation pathway, and its degradation has been postulated to...